Heron Therapeutics Inc SEC Filings

Heron Therapeutics (HRTX) reported an initial statement of beneficial ownership on Form 3 for director Thomas P. Cusack. The filing states that, as of the event date 10/27/2025, no securities are beneficially owned.

The report indicates it was filed by one reporting person and lists no non-derivative or derivative holdings, with the explanation: “No securities are beneficially owned.” The signature is provided by an attorney-in-fact on behalf of the reporting person.

Heron Therapeutics (HRTX): Officer William P. Forbes reported an RSU vesting and settlement. On 10/31/2025, 11,694 shares of common stock were acquired from restricted stock units at a price of $0.00 per share (Transaction Code M). Following this, he beneficially owned 166,203 shares directly. The filing also lists 152,027 restricted stock units remaining after the transaction.

Each restricted stock unit represents the right to receive one share of common stock. The RSUs vest in 16 equal installments beginning one quarter after the grant date, January 31, 2025.

Heron Therapeutics (HRTX) reported an insider transaction by EVP & Chief Financial Officer Ira Duarte. On 10/31/2025, 11,694 shares of common stock were acquired upon settlement of restricted stock units. After this transaction, 179,786 common shares are beneficially owned directly, and 152,027 restricted stock units remain outstanding. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.

Heron Therapeutics (HRTX) reported an insider transaction: CEO and Director Craig Collard acquired 34,789 shares of common stock on 10/31/2025 through settlement of restricted stock units (transaction code M) at $0.

Following the transaction, Collard directly owned 523,124 shares. He also beneficially owned 452,253 RSUs after the event. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.

Heron Therapeutics (HRTX) reported Q3 2025 results with net product sales of $38.2 million, up from $32.8 million a year ago. Gross profit was $26.3 million and the company posted a net loss of $17.5 million, or $0.10 per share. Cash and cash equivalents were $43.1 million, and cash plus short‑term investments totaled $55.5 million as of September 30, 2025.

Product mix showed CINVANTI at $24.0 million, ZYNRELEF $9.3 million, APONVIE $3.0 million, and SUSTOL $1.9 million. Heron refinanced its balance sheet: it amended its Hercules working capital facility to up to $150.0 million and drew $110.8 million; exchanged and extinguished $150.0 million of 2026 convertible notes (including issuing 16.67 million shares for $25.0 million of principal and paying $125.0 million in cash); and issued $35.0 million of 2031 convertible notes. It also raised $27.7 million gross via a private placement of common and Series A preferred stock. The quarter included $11.3 million in loss on debt extinguishment. Management believes its cash, cash equivalents and short‑term investments are sufficient for at least one year.

Heron Therapeutics (HRTX) furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 to this report and is provided under Item 2.02.

The company states the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under the Exchange Act. The filing date is November 4, 2025.

Heron Therapeutics (HRTX) appointed Thomas Cusack to its Board of Directors, effective October 27, 2025. He will serve until the Company’s 2026 Annual Meeting of Stockholders and join the Nominating and Corporate Governance Committee. The appointment was made pursuant to a Cooperation Agreement between the Company and Rubric Capital Management LP dated August 8, 2025.

The Company states there are no transactions involving Mr. Cusack requiring disclosure under Item 404(a). He will receive compensation under Heron’s standard program for non-employee directors as described in the April 30, 2025 proxy statement, and will enter into the Company’s standard Director Indemnification Agreement, with the form to be filed with the 2025 Form 10-K. A press release dated October 29, 2025 was furnished as Exhibit 99.1.

Heron Therapeutics (HRTX) reported an insider equity change. EVP & Chief Development Officer William P. Forbes acquired 3,874 shares of common stock on 10/19/2025 via the conversion of restricted stock units (transaction code M). Following this event, he directly owns 154,509 shares of common stock. The filing also lists 34,869 derivative securities remaining as restricted stock units. Each RSU equals one share, and the RSUs vest in 16 equal quarterly installments beginning one quarter after 01/19/2024.

Heron Therapeutics (HRTX) reported an insider equity change by EVP & CFO Ira Duarte on 10/19/2025. A tranche of 3,874 shares of common stock was acquired upon the vesting/settlement of restricted stock units, reflected as a transaction code M.

Following the transaction, Duarte directly beneficially owns 168,092 shares of common stock and 34,869 RSUs. Each RSU represents the right to receive one share of common stock. The RSUs vest in 16 equal quarterly installments beginning one quarter after the grant date of 01/19/2024.